Corticosteroid Prophylaxis for Neurologic Complications of Intravenous Immunoglobulin G Therapy in Childhood Immune Thrombocytopenic Purpura

1999 ◽  
Vol 21 (6) ◽  
pp. 514-517 ◽  
Author(s):  
Somasundaram Jayabose ◽  
Mamoon Mahmoud ◽  
Oya Levendoglu-Tugal ◽  
Claudio Sandoval ◽  
Fevzi Ozkaynak ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Immune Thrombocytopenic Purpura ◽  
Neurologic Complications ◽  
Thrombocytopenic Purpura ◽  
Intravenous Immunoglobulin G

Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies

Blood ◽  
2006 ◽  
Vol 108 (3) ◽  
pp. 943-946 ◽  
Author(s):  
Michelle Lee Webster ◽  
Ebrahim Sayeh ◽  
Min Crow ◽  
Pingguo Chen ◽  
Bernhard Nieswandt ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Intravenous Immunoglobulin ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Immunoglobulin G ◽  
Ivig Treatment ◽  
Relative Efficacy ◽  
Thrombocytopenic Purpura ◽  
Antiplatelet Antibodies ◽  
Intravenous Immunoglobulin G

Abstract Intravenous immunoglobulin G (IVIG) is used to treat idiopathic thrombocytopenic purpura (ITP). Although many patients benefit from IVIG, some are refractory to this therapy. ITP is characterized by platelet clearance mediated primarily by antiplatelet antibodies against GPIIbIIIa and/or the GPIbα complex. These 2 groups of antibodies may induce ITP through different mechanisms. We tested the hypothesis that IVIG may not be equally effective in preventing ITP caused by anti-GPIIbIIIa versus anti-GPIbα antibodies in mice. Thrombocytopenia was induced in BALB/c mice using monoclonal antibodies against either mouse GPIIbIIIa (JON1, JON2, and JON3) or GPIbα (p0p3, p0p4, p0p5, p0p9, and p0p11). Pretreatment with IVIG significantly ameliorated ITP in all anti-GPIIbIIIa–injected animals. Conversely, IVIG failed to prevent ITP in all anti-GPIbα–treated mice, except for p0p4. These results were repeated in C57BL/6 mice, and with different IVIG preparations. These data in mice suggest that patients with ITP mediated by anti-GPIbα antibodies may be less responsive to IVIG treatment.

Sign in / Sign up

Export Citation Format

Share Document